Otitis media (OM), inflammation of the middle ear, remains the most common cause of hearing impairment in children. It is also the most common cause of surgery in children in the developed world. There is evidence from studies of the human population and mouse models that there is a significant genetic component predisposing to OM, yet nothing is known about the underlying genetic pathways involved in humans. We identified an N-ethyl-N-nitrosourea-induced dominant mouse mutant Junbo with hearing loss due to chronic suppurative OM and otorrhea. This develops from acute OM that arises spontaneously in the postnatal period, with the age of onset and early severity dependent on the microbiological status of the mice and their air quality. We have identified the causal mutation, a missense change in the C-terminal zinc finger region of the transcription factor Evi1. This protein is expressed in middle ear basal epithelial cells, fibroblasts, and neutrophil leukocytes at postnatal day 13 and 21 when inflammatory changes are underway. The identification and characterization of the Junbo mutant elaborates a novel role for Evi1 in mammalian disease and implicates a new pathway in genetic predisposition to OM.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592239PMC
http://dx.doi.org/10.1371/journal.pgen.0020149DOI Listing

Publication Analysis

Top Keywords

otitis media
8
middle ear
8
mutation evi1
4
evi1 locus
4
locus junbo
4
junbo mice
4
mice susceptibility
4
susceptibility otitis
4
media otitis
4
media inflammation
4

Similar Publications

Objectives: Chronic otitis media (COM) is a prevalent condition affecting auditory function. Ossiculoplasty is a known treatment strategy, but its effectiveness concerning the presence of cholesteatoma has not been extensively studied.

Methods: We conducted a multicentre study involving 153 patients diagnosed with COM without cholesteatoma (ncCOM) and with cholesteatoma (cCOM).

View Article and Find Full Text PDF

Importance: A high infection burden in early childhood is common and a risk factor for later disease development. However, longitudinal birth cohort studies investigating early-life infection burden and later risk of infection and antibiotic episodes are lacking.

Objective: To investigate whether early-life infection burden is associated with a later risk of infection and systemic antibiotic treatment episodes in childhood.

View Article and Find Full Text PDF

Objective: Chronic otitis media (COM) is characterized by chronic, intermittent, or persistent discharge through a perforated tympanic membrane. In this study, we aimed to evaluate the postoperative audiological outcomes in middle-aged patients compared to younger patients who underwent tympanoplasty with mastoidectomy via post-auricular approach for the treatment of COM.

Methods: This prospective interventional study included patients admitted in wards from August 2017 to January 2019 at the Department of Otorhinolaryngology, Jawaharlal Nehru Medical College and Hospital, Aligarh, India.

View Article and Find Full Text PDF

Facial paralysis is an infrequent and serious potential complication of acute otitis media (AOM). We describe a pediatric case of rapidly progressive facial paralysis as a secondary complication alongside AOM, caused by the non-typeable  (NTHi) strain, which was managed with facial nerve decompression, glucocorticoid medication, and antimicrobial chemotherapy. The reasons why NTHi becomes pathogenic in certain patients are not yet fully understood, and the specific interactions and adaptations that lead to complications must be further investigated, as they result in more complex treatment approaches.

View Article and Find Full Text PDF

Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis.

Braz J Otorhinolaryngol

January 2025

Tokushima University Graduate School, Institute of Biomedical Sciences, Department of Otolaryngology-Head and Neck Surgery, Tokushima, Japan.

Objective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma. Biologics are not indicated for EOM; however, because approximately 10% of ECRS cases has concomitant EOM, concomitant EOM improvement has been observed when dupilumab is administered for ECRS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!